The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled. 17 November 2026 Last updated : 17 November 2026 BonTrade The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.